Total direct medical costs of heart failure (HF) in the U.S. were estimated to be $21 billion in 2012 and projected to increase to $53 billion by 2030. Treatment for fluid overload in HF patients is one of the most common causes of hospital inpatient admissions in patients age 65 and over. This report identifies the rate and costs of HF admissions, the costs in the 30 days after HF admissions, and the percentage of HF admissions that are readmissions. It also identifies the rate and costs of treatment for worsening HF in the outpatient setting in cases where inpatient admission does not occur.
This report was commissioned by scPharmaceuticals, Inc.